Compare MPLX LP (MPLX) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MPLX LP vs Novartis AG — how do they compare? MPLX LP trades at $60.05 (market cap $60.66B), while Novartis AG trades at $139.36 (market cap $262.64B). The key difference: Novartis AG is far larger — about 4.3× MPLX LP's market cap, and MPLX LP pays the higher dividend (7.2%). Which is the better fit depends on your goals.
| MPLX | NVS | |
|---|---|---|
Market Cap | $60.66B | $262.64B |
Sector | Technology | Health |
52-Week High | $60.51 | $168.62 |
52-Week Low | $47.80 | $121.80 |
Enterprise Value | $85.76B | $303.97B |
Dividend Yield | 7.2% | 3.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPLX trades at $59.83, up 0.27% with strong technical momentum as moving averages signal bullish conditions. The company demonstrates robust profitability with 40.45% net income margin and 33.95% ROE, though recent Q2 2026 earnings matched expectations without beating. Analyst consensus remains strongly bullish with 19 buy ratings and a $64.00 price target, representing 7% upside potential. Recent news highlights management's commitment to 12.5% annual distribution growth through 2027.
MPLX offers attractive income with 7%+ yield and distribution growth potential, supported by fee-based midstream operations. Key risks include rising leverage approaching 4x and exposure to energy market volatility. The stock presents a compelling value proposition for income-focused investors seeking energy infrastructure exposure with growth catalysts from ongoing capacity expansions.
Novartis (NVS) stock is trading at $137.7, down 13.93% over 24 hours following negative clinical trial news. The technical outlook is bearish with support at $133 and resistance at $138. Fundamentally, the company maintains strong profitability with a 22.5% net income margin and $56.67B revenue in 2025, though recent pipeline setbacks have pressured sentiment. Analyst consensus is mixed with 24% buy ratings but 68% hold, reflecting caution amid growth uncertainties.
The investment outlook is clouded by recent trial failures, but Novartis' solid cash flow and reiterated 5-6% revenue growth guidance through 2030 provide a foundation. Key risks include pipeline execution and competitive threats, while institutional ownership trends will be critical to watch for stability signals. The stock offers value if management can navigate current headwinds effectively.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
